AACR: Promising Phase I Clinical Data With Pan-AKT Inhibitor in Solid Tumors

Different dosing schedules of the pan-AKT inhibitor AZD5363 revealed key details about maximum tolerable dosages, and biochemical efficacy was suggested by analyzing biomarkers, according to the results of a phase I study presented at the 2013 annual meeting of the American Association of Cancer Research.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news